维诺德·巴拉钱德兰博士在斯隆—凯特林癌症研究所（MSK）的一则新闻稿中表示：“新出炉的一期实验数据十分喜人。数据显示，这款试验治疗性mRNA疫苗有望在接种数年之后激活能够把胰腺癌识别为异物的抗肿瘤T细胞。”该研究由斯隆—凯特林癌症研究所旗下奥拉扬癌症 ...

近日，荣灿生物医药技术（上海）有限公司（以下简称“荣灿生物”）在mRNA创新药物研发领域取得重要进展，其自主研发的脂质纳米颗粒（LNP）递送技术成功获得美国专利授权。这是继中国内地和香港地区14项专利授权后，荣灿生物在知识产权领域的又一突破，标志着公司在mRNA相关技术领域的创新成果获得国际认可，进一步巩固了其在核酸药物递送领域的技术储备，为后续创新药物研发提供了关键的技术支持。

“While mRNA delivery systems offer a powerful method for achieving transgene-free genome editing, they remain inefficient and challenging in plants,” the team wrote in a paper published in the ...

The trial is jointly conducted at the Fudan University Shanghai Cancer Center and Peking University Cancer Hospital.

mRNA technology was quickly adopted in the COVID-19 vaccine race and has undoubtedly proven its worth. Less than a year after the emergence of COVID-19, an entirely new type of vaccine based on ...

The "mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com ...

saw its share prices grow by 5.34 percent on Friday to finish at $35.53 apiece following news that a new coronavirus with pandemic potential was discovered in China. MRNA traded higher in line ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other ...